Hematopoiesis News 10.09 March 12, 2019 | |
| |
TOP STORYInterrogation of Human Hematopoiesis at Single-Cell and Single-Variant Resolution Scientists performed genetic fine-mapping for blood cell traits in the UK Biobank to identify putative causal variants. These variants were enriched in genes encoding proteins in trait-relevant biological pathways and in accessible chromatin of hematopoietic progenitors. [Nat Genet] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers showed that the NAD+ -boosting agent nicotinamide riboside reduced mitochondrial activity within HSCs through increased mitochondrial clearance, leading to increased asymmetric HSC divisions. [Cell Stem Cell] Abstract | Press Release | Graphical Abstract Investigators showed that Regnase-1 regulated self-renewal of hematopoietic stem and progenitor cells through modulating the stability of Gata2 and Tal1 mRNA. In addition, they found that dysfunction of Regnase-1 led to the rapid onset of abnormal hematopoiesis. [Nat Commun] Full Article | Press Release BRD4 Directs Hematopoietic Stem Cell Development and Modulates Macrophage Inflammatory Responses ChIP-seq analysis showed that despite its limited importance, BRD4 broadly occupied the macrophage genome and participated in super-enhancer (SE) formation. Although BRD4 was critical for SE formation in cancer, BRD4 was not required for macrophage SEs, as knockout macrophages created alternate, BRD4-less SEs that compensated BRD4 loss. [EMBO J] Full Article | Graphical Abstract Chromatin Remodeling Mediated by ARID1A Is Indispensable for Normal Hematopoiesis in Mice The authors demonstrated that ARID1A was essential for maintaining the frequency and function of HSCs and its loss impaired the differentiation of both myeloid and lymphoid lineages. ARID1A deficiency led to a global reduction in open chromatin and ensuing transcriptional changes affected key genes involved in hematopoietic development. [Leukemia] Full Article Using in vitro differentiation systems, investigators revealed that CBFβ-MYH11 knockdown interfered with normal megakaryocyte maturation. Two pivotal regulators, GATA2 and KLF1, were identified to complementally occupy RUNX1-binding sites upon fusion protein knockdown, and overexpression of GATA2 partly induced a gene program involved in megakaryocyte-directed differentiation. [Blood Cancer J] Full Article Scientists report that individual adult human CD49f+ long-term HSCs (LT-HSCs) could be reprogrammed into induced pluripotent stem cells at close to 50% efficiency using Sendai virus transduction. This sensitivity to reprogramming was specific to LT-HSCs, since it progressively decreased in committed progenitors. [Cell Rep] Full Article | Graphical Abstract Enhanced Transduction of Macaca fascicularis Hematopoietic Cells with Chimeric Lentiviral Vectors Capsid modification increased transduction efficiency in all hematopoietic cells tested, including hematopoietic progenitor cells, repopulating cells, and T cells from Mauritian Macaca fascicularis, regardless of vector structure or purification method. [Hum Gene Ther] Abstract CLINICAL RESEARCHOutcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy Median interval between multiple myeloma diagnosis and refractoriness to CD38-targeting monoclonal antibodies (T0) was 50.1 months. The median overall survival from T0 for the entire cohort was 8.6 months, ranging from 11.2 months for patients not simultaneously refractory to an immunomodulatory agent and a proteasome inhibitor to 5.6 months for “penta-refractory” patients. [Leukemia] Abstract Investigators aimed to determine the safety and efficacy of combining a janus kinase (JAK)-inhibitor with ibrutinib because JAK-mediated cytokine-signals support chronic lymphocytic leukemia cells and may not be inhibited by ibrutinib. [Cancer Med] Full Article Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSOncogenic Deregulation of Cell Adhesion Molecules in Leukemia Focusing on myeloid leukemia, the authors provide a current overview of the mechanisms by which leukemogenic gene products hijack control of cellular adhesion to subsequently disturb normal hematopoiesis and promote leukemia development. [Cancers] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSOrchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD Orchard Therapeutics announced that new clinical data from the registrational trial of OTL-200 in metachromatic leukodystrophy (MLD) will be featured in an oral presentation. [Press release from Orchard Therapeutics discussing research to be presented at 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT), Frankfurt] Press Release | |
| |
INDUSTRY NEWSSTEMCELL Technologies Wins Deloitte Best Managed Companies Award STEMCELL Technologies announced that the company has been selected as a winner of Canada’s Best Managed Companies program for 2019. Canada’s Best Managed Companies is the country’s leading business awards program, recognizing excellence in the management abilities and practices of Canadian owned and managed companies with revenues over $15 million. [STEMCELL Technologies, Inc.] Press Release Bio-Path Holdings, Inc. announced a clinical update to the previously reported interim analysis from the Phase II trial of prexigebersen for the treatment of acute myeloid leukemia and provided its plans for the compound’s clinical development moving forward toward registration. [Bio-Path Holdings, Inc.] Press Release Pluristem Therapeutics, Inc. announced that the company has fully enrolled the second cohort of six patients in its ongoing Phase I clinical study evaluating PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation, and has received Data and Safety Monitoring Board approval to continue to the final cohort of the study. [Pluristem Therapeutics, Inc.] Press Release Secura Bio Acquires Global Rights to Farydak® Secura Bio, Inc. announced that it has acquired the global rights to Farydak® from Novartis. Farydak® is a prescription oral medication used in combination with proteasome inhibitors and corticosteroids to treat patients with relapsed or refractory multiple myeloma who had received prior treatments. [Secura Bio, Inc. (PR Newswire Association LLC.)] Press Release Genentech announced the submission of a supplemental New Drug Application to the US FDA for Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions. [Genentech, Inc.] Press Release | |
| |
POLICY NEWSVanderbilt Panel Weighs In Against Tenure for #MeToo Scientist A faculty grievance committee last month upheld a decision to deny tenure to BethAnn McLaughlin, a neuroscientist at the Vanderbilt University School of Medicine in Nashville who has become a prominent spokesperson for the #MeToo movement in science. [ScienceInsider] Editorial Ned Sharpless, Director of the National Cancer Institute, to Be Named Acting FDA Commissioner The Trump administration announced it would name Ned Sharpless, the director of the National Cancer Institute, the acting commissioner of the FDA next month. The announcement came just a week after the current commissioner, Scott Gottlieb, announced he plans to resign in early April. [STAT News] Editorial
| |
EVENTSNEW 2019 ASCO Annual Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Studies Scholarship – Stem Cells & Erythropoiesis in MDS (Karolinska Institutet) NEW Research Scientist – Leukemia Stem/Progenitor Cells (MD Anderson Cancer Center) Associate Scientist – Immuno-Oncology (HMH Center for Discovery & Innovation) Postdoctoral Scientist – Lymphocyte/Leukemia Research (City of Hope) Assistant Professor – Sarcoma or Skeletal Related Malignancies (University of California, Davis) Postdoctoral Position – RNA Modifications, Hematopoiesis & Cancer (Lund University) Postdoctoral Research Fellow – Development of Lymphoid Cells (Lund University) Investigator Positions – Hematologic Malignancies (University of Alabama Birmingham) Postdoctoral Associate – T-ALL Research (University of New Mexico) Faculty Positions – Hematology and Oncology (University of California, Davis) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|